Sermorelin 5mg
Sermorelin – GHRH (1-29) analog, studied in relation to endogenous growth hormone release. Price and batch analysis.
59.00 EUR · In stock
This product is intended solely for scientific and research use, as well as for use as a reference standard in HPLC analysis, and is not an approved medicinal product. It is not intended for the diagnosis, treatment or prevention of disease in humans or animals. It has not been approved by the FDA, the EMA or any national regulator. The information on this page is provided for scientific information purposes only and does not constitute medical advice, a recommendation for use, or any claim of clinical efficacy or safety.
Sermorelin – What the Peptide Is
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), reproducing the first 29 amino acids of the natural molecule. This truncated sequence is sufficient to preserve biological activity, which is why the compound is designated as GHRH (1-29).
Natural GHRH is produced in the hypothalamus and reaches the anterior pituitary gland, where it stimulates the synthesis and release of growth hormone. Sermorelin reproduces precisely this stage of the regulatory chain.
An essential feature of the compound is that it acts on endogenous regulation rather than replacing the hormone. Release remains subject to natural feedback mechanisms, including the inhibitory action of somatostatin.
Mechanism of Action
The molecule binds to the GHRH receptor on somatotropic cells in the anterior pituitary gland. Binding activates an intracellular signaling pathway, leading to an increase in cyclic adenosine monophosphate and subsequent release of stored growth hormone.
Since the effect is on the pituitary gland rather than on peripheral tissues, release retains its pulsatile character. This pulsatile profile is discussed in the literature as a significant difference compared to direct administration of growth hormone, in which concentrations are maintained continuously.
The half-life of the molecule in circulation is short – on the order of minutes. This also determines the short-lived nature of the release that follows binding.
Research Data and Observations
Published observations focus on the concentrations of growth hormone and insulin-like growth factor-1 (IGF-1) after administration. IGF-1 is used as a more stable indicator, as it reflects integrated release over a longer period.
A separate line of research examines the age-related decline in growth hormone release and the extent to which the pituitary's response to GHRH stimulation is preserved with advancing age.
Significant individual variability in response is noted, attributed to differences in pituitary reserve and somatostatin tone at the time of measurement.
When interpreting published data, the difference between preclinical and clinical conditions should be taken into account. Results from cell cultures and animal models describe mechanism but do not allow quantitative conclusions for human conditions.
Dose ranges used in preclinical studies are often not directly translatable due to differences in metabolism between species. This limitation is consistently noted in review works.
Example Calculations
The calculations below are purely mathematical examples showing the relationship between the total amount of substance, the volume of solvent, and the resulting concentration. They do not represent a dosing recommendation, administration schedule, or instructions for use.
When dissolving 5 mg with 2 ml of bacteriostatic water:
The resulting concentration is 2.5 mg/ml, with 0.40 ml containing 1 mg of substance.
Example values:
- 0.1 ml = 0.25 mg
- 0.2 ml = 0.5 mg
- 0.3 ml = 0.75 mg
- 0.4 ml = 1 mg
- 0.5 ml = 1.25 mg
Overview of Scientific Publications
Sermorelin is among the longer-documented compounds in this group, with literature covering both diagnostic applications and studies on regulation of the growth axis.
Comparison with newer GHRH analogs requires caution, as they differ in resistance to enzymatic degradation and in duration of action.
Safety data from studies
Observations described in the literature include reactions at the injection site and short-lived vascular manifestations related to vasodilation. A concentration-dependent relationship is noted.
Due to the short half-life of the molecule, the described manifestations are usually of limited duration.
A general limitation for compounds in this category is the absence of long-term controlled studies in humans. Available information describes mechanism and short-term observations, not a safety profile for prolonged use.
This product is intended exclusively for research purposes. It is not a food, food supplement, or medicinal product and is not intended for the diagnosis, treatment, or prevention of disease.